Update on systemic therapies of metastatic renal cell carcinoma (Q37697631)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 February 2010

edit

Language	Label	Description	Also known as
English	Update on systemic therapies of metastatic renal cell carcinoma	scientific article published on 24 February 2010

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20180125

retrieved

22 August 2017

review article

1 reference

stated in

Europe PubMed Central

title

Update on systemic therapies of metastatic renal cell carcinoma (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20180125

retrieved

22 August 2017

author name string

E Herrmann

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20180125

retrieved

22 August 2017

S Bierer

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20180125

retrieved

22 August 2017

C Wülfing

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20180125

retrieved

22 August 2017

publication date

24 February 2010

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20180125

retrieved

22 August 2017

published in

World Journal of Urology

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20180125

retrieved

22 August 2017

volume

28

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20180125

retrieved

22 August 2017

issue

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20180125

retrieved

22 August 2017

page(s)

303-309

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20180125

retrieved

22 August 2017

cites work

Sunitinib efficacy against advanced renal cell carcinoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy in metastatic renal cell carcinoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2008

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential therapies in metastatic renal cell carcinoma: option or strategy?

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence and long-term prognosis of papillary renal cell carcinoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeted therapy in renal cell carcinoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy for renal cell carcinoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/20180125

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S00345-010-0519-5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20180125

retrieved

22 August 2017

PubMed publication ID

20180125

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20180125

retrieved

22 August 2017

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37697631&oldid=2200820930"